drugset / Trial / NCT00907530

Study to Compare MultiHance With Gadovist in Magnetic Resonance Imaging (MRI) of the Brain

NCT00907530

Phase 4 Completed 121 enrolled Bracco Diagnostics, Inc
RandomizedCrossoverDouble-blindDiagnostic

Summary

This study is being conducted as a phase IV, double-blind, multi-center, randomized, crossover trial aimed at a within-subject comparison of MULTIHANCE and GADOVIST at a dose of 0.1 mmol/kg, in terms of qualitative and quantitative assessment of unenhanced MRI (UE MRI) and contrast-enhanced MRI (CE MRI) for the visualization of brain disease.

Timeline

Start
2009-09
Primary completion
2011-03
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gadobenate dimeglumine Diagnostic / imaging agent 0.1 unknown
Comparator Gadobutrol Diagnostic / imaging agent 0.1 unknown

Indications

No indication recorded.